

**CONTESTING RECORD PROCEDURES:**

Individuals desiring to contest or amend information maintained in the system should direct their request to the Office of the Assistant Attorney General, Civil Division, 950 Pennsylvania Avenue, NW., Washington, DC 20530. The request should clearly and concisely state what information is being contested, the reason(s) for contesting it, and the proposed amendment to the record.

**RECORD SOURCE CATEGORIES:**

Individuals submitting information who are seeking to be included in the Department of Justice list of annuity brokers.

**SYSTEMS EXEMPTED FROM CERTAIN PROVISIONS OF THE ACT:**

None.

[FR Doc. 03-8641 Filed 4-8-03; 8:45 am]

**BILLING CODE 4410-12-P**

**DEPARTMENT OF JUSTICE****Drug Enforcement Administration****Manufacturer of Controlled Substances; Notice of Registration**

By Notice dated August 28, 2002, and published in the **Federal Register** on October 18, 2002, (67 FR 64417), AccuStandard, Inc., 125 Market Street, New Haven, Connecticut 06513, made application by letter to the Drug Enforcement Administration (DEA) to be registered as a bulk manufacturer of the basic classes of controlled substances listed below:

Drug	Schedule
N-Ethylamphetamine (1475) .....	I
N,N-Dimethylamphetamine (1480) .....	I
Fenethylline (1503) .....	I
Mecloqualone (2572) .....	I
Alpha-Ethyltryptamine (7249) .....	I
3,4,5-Trimethoxyamphetamine (7390) .....	I
2,5-Dimethoxy-4-ethylamphetamine (7399) .....	I
5-Methoxy-3,4-methylenedioxyamphetamine (7401) .....	I
Diethyltryptamine (7434) .....	I
Dimethyltryptamine (7435) .....	I
Psilocybin (7437) .....	I
Psilocyn (7438) .....	I
N-Ethyl-1-phenylcyclohexylamine (7455) .....	I
1-(1-Phenylcyclohexyl) pyrrolidine (PCPY) (7458) .....	I
1-[1-(2-Thienyl)cyclohexyl] pyrrolidine (TCPY) (7473) .....	I
N-Ethyl-3-piperidyl benzilate (7482) .....	I
N-Methyl-3-piperidyl benzilate (7484) .....	I

Drug	Schedule
Acetyldihydrocodeine (9051) .....	I
Benzylmorphine (9052) .....	I
Desomorphine (9055) .....	I
Codeine methylbromide (9070) .....	I
Difenoxin (9168) .....	I
Hydromorphenol (9301) .....	I
Methyldihydromorphine (9304) .....	I
Morphine methylbromide (9305) .....	I
Morphine methylsulfonate (9306) .....	I
Nicomorphine (9312) .....	I
Drotebanol (9335) .....	I
Allylprodine (9602) .....	I
Alphamethadol (9605) .....	I
Betaprodine (9611) .....	I
Clonitazene (9612) .....	I
Dextromoramide (9613) .....	I
Diampromide (9615) .....	I
Diethylthiambutene (9616) .....	I
Dimenoxadol (9617) .....	I
Dimepheptanol (9618) .....	I
Dimethylthiambutene (9619) .....	I
Dioxaphetyl butyrate (9621) .....	I
Dipipanone (9622) .....	I
Ethylmethylthiambutene (9623) .....	I
Furethidine (9626) .....	I
Hydroxypethidine (9627) .....	I
Ketobemidone (9628) .....	I
Morpheridine (9632) .....	I
Noracymethadol (9633) .....	I
Normethadone (9635) .....	I
Norpipanone (9636) .....	I
Phenadoxone (9637) .....	I
Phenampromide (9638) .....	I
Phenoperidine (9641) .....	I
Piritramide (9642) .....	I
Proheptazine (9643) .....	I
Propiridine (9644) .....	I
Propiram (9649) .....	I
1-Methyl-4-phenyl-4-propionoxypiperidine (9661) .....	I
1-(2-Phenylethyl)-4-phenyl-4-acetoxypiperidine (9663) .....	I
Tilidine (9750) .....	I
Para-Fluorofentanyl (9812) .....	I
3-Methylfentanyl (9813) .....	I
Alpha-Methylfentanyl (9814) .....	I
Acetyl-alpha-methylfentanyl (9815) .....	I
Beta-Hydroxyfentanyl (9830) .....	I
Beta-Hydroxy-3-methylfentanyl (9831) .....	I
Alpha-Methylthiofentanyl (9832) .....	I
3-Methylthiofentanyl (9833) .....	I
Thiofentanyl (9835) .....	I
Nabilone (7379) .....	II
1-Phenylcyclohexylamine (7460) .....	II
Phenylacetone (8501) .....	II
1-Piperidinocyclohexanecarbonitrile (8603) .....	II
Isomethadone (9226) .....	II
Metopon (9260) .....	II
Piminodine (9730) .....	II
Racemorphan (9733) .....	II
Bezitramide (9800) .....	II

The firm plans to manufacture small quantities of the listed controlled substances to make reference standards.

No comments or objections have been received. DEA has considered the factors in Title 21, United States Code, section 823(a) and determined that the

registration of AccuStandard, Inc. to manufacture the listed controlled substances is consistent with the public interest at this time. DEA has investigated AccuStandard, Inc. to ensure that the company's registration is consistent with the public interest. This investigation included inspection and testing of the company's physical security systems, verification of the company's compliance with state and local laws, and a review of the company's background and history. Therefore, pursuant to 21 U.S.C. 823 and 28 CFR 0.100 and 0.104, the Deputy Assistant Administrator, Office of Diversion Control, hereby orders that the application submitted by the above firm for registration as a bulk manufacturer of the basic classes of controlled substances listed is granted.

Dated: March 21, 2003.

**Laura M. Nagel,**

*Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration.*

[FR Doc. 03-8588 Filed 4-8-03; 8:45 am]

**BILLING CODE 4410-09-M**

**DEPARTMENT OF JUSTICE****Drug Enforcement Administration****Manufacturer of Controlled Substances; Notice of Application**

Pursuant to § 1301.33(a) of Title 21 of the Code of Federal Regulations (CFR), this is notice that on February 14, 2003, Boehringer Ingelheim Chemicals, Inc., 2820 N. Normandy Drive, Petersburg, Virginia 23805, made application by renewal, and on November 27, 2002, made application by renewal, and on November 27, 2002, made application by letter to the Drug Enforcement Administration (DEA) for registration as a bulk manufacturer of the basic classes of controlled substances listed below:

Drug	Schedule
Amphetamine (1100) .....	II
Methadone (9250) .....	II
Methadone-intermediate (9254) .....	II
Methylphenidate (1724) .....	II
Levo-alphaacetylmethadol (9648) .....	II
Fentanyl (9801) .....	II
Dextropropoxyphene (9273) .....	II

The firm plans to manufacture the listed controlled substances for formulation into finished pharmaceuticals.

Any other such applicant and any person who is presently registered with DEA to manufacture such substances may file comments or objections to the issuance of the proposed registration.